Systematic determination of the packaging limit of lentiviral vectors
- PMID: 11589831
- DOI: 10.1089/104303401753153947
Systematic determination of the packaging limit of lentiviral vectors
Abstract
Because of their ability to transduce nondividing cells, human immunodeficiency virus type 1 (HIV)-based vectors have great potential for the therapeutic delivery of genes to cells. We describe here a systematic study of the packaging limit of HIV-based vectors. Restriction endonuclease-generated bacterial chromosomal DNA fragments of different lengths were cloned at three different positions within a lentiviral vector. Vesicular stomatitis virus G protein (VSV G) pseudotyped lentiviral particles were prepared and the different clones were titered on mammalian cells. We observed that the restriction endonuclease site positions at the 5' and 3' ends of the genome were superior with regard to insertional capacity of foreign DNA. In all cases, viral titers decreased semi-logarithmically with increasing vector length. There appears to be no absolute packaging limit because measurable titers were obtained even when the proviral length was in excess of 18 kb. The reduction in titer appears to occur at the level of viral encapsidation, although we cannot exclude limitations in nuclear export of proviral RNA. These results suggest that HIV-based vectors may have a secondary advantage over oncoretroviral vectors because of their greater packaging limit, although the very low titers of the larger vectors will be of limited utility.
Similar articles
-
RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors.Exp Biol Med (Maywood). 2010 Oct;235(10):1269-76. doi: 10.1258/ebm.2010.010053. Epub 2010 Sep 27. Exp Biol Med (Maywood). 2010. PMID: 20876083
-
Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.J Gene Med. 2005 Jun;7(6):818-34. doi: 10.1002/jgm.726. J Gene Med. 2005. PMID: 15693055
-
Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA.Hum Gene Ther. 2000 Sep 20;11(14):2025-37. doi: 10.1089/10430340050143444. Hum Gene Ther. 2000. PMID: 11020801
-
Altering the tropism of lentiviral vectors through pseudotyping.Curr Gene Ther. 2005 Aug;5(4):387-98. doi: 10.2174/1566523054546224. Curr Gene Ther. 2005. PMID: 16101513 Free PMC article. Review.
-
Lentiviral vectors for gene delivery into cells.DNA Cell Biol. 2002 Dec;21(12):937-51. doi: 10.1089/104454902762053873. DNA Cell Biol. 2002. PMID: 12573051 Review.
Cited by
-
Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy.Leukemia. 2015 Oct;29(10):2024-32. doi: 10.1038/leu.2015.103. Epub 2015 Apr 27. Leukemia. 2015. PMID: 25915825
-
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.Cancers (Basel). 2020 Aug 5;12(8):2175. doi: 10.3390/cancers12082175. Cancers (Basel). 2020. PMID: 32764348 Free PMC article. Review.
-
Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models.Mol Ther. 2021 Sep 1;29(9):2691-2706. doi: 10.1016/j.ymthe.2021.05.006. Epub 2021 May 8. Mol Ther. 2021. PMID: 33974997 Free PMC article.
-
The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virus.Retrovirology. 2012 Nov 6;9:92. doi: 10.1186/1742-4690-9-92. Retrovirology. 2012. PMID: 23131071 Free PMC article. Review.
-
Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.Pharmacol Res. 2010 Jan;61(1):14-26. doi: 10.1016/j.phrs.2009.10.002. Epub 2009 Oct 17. Pharmacol Res. 2010. PMID: 19840853 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources